Updated Reviewed

Management of Medication Toxicity or Intolerance

Rash and Hypersensitivity Reactions

View full version of Table 17k.
Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions
Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions
  
  
  
  

References

  1. Pelchen-Matthews A, Larsen JF, Shepherd L, et al. Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study. HIV Res Clin Pract. 2021;22(6):160-168. Available at: https://pubmed.ncbi.nlm.nih.gov/34779362.
  2. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS. 2011;25(10):1271-1280. Available at: https://pubmed.ncbi.nlm.nih.gov/21505298.
  3. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS. 2008;22(4):540-541. Available at: https://pubmed.ncbi.nlm.nih.gov/18301070.
  4. Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the Phase II PIANO study. HIV Med. 2014;15(9):513-524. Available at: https://pubmed.ncbi.nlm.nih.gov/24589294.
  5. Thomas SJ, Kilgore JT, Becken BA, Cunningham CK, Thompson AB. Raltegravir-associated drug-reaction with eosinophilia and systemic symptoms syndrome in a pediatric patient without characteristic human leukocyte antigen B*57:01 or B*53:01 alleles. J Pediatric Infect Dis Soc. 2021;10(3):363-366. Available at: https://pubmed.ncbi.nlm.nih.gov/32766769.
  6. Thomas M, Hopkins C, Duffy E, et al. Association of the HLA-B*53:01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir. Clin Infect Dis. 2017;64(9):1198-1203. Available at: https://pubmed.ncbi.nlm.nih.gov/28369189.
  7. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27(9):1403-1412. Available at: https://pubmed.ncbi.nlm.nih.gov/23343913.
  8. Shah R, Nabiswa H, Okinda N, Revathi G, Hawken M, Nelson M. Prevalence of HLA-B*5701 in a Kenyan population with HIV infection. J Infect. 2018;76(2):212-214. Available at: https://pubmed.ncbi.nlm.nih.gov/28919349.
  9. Rutstein RM, Samson P, Fenton T, et al. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group protocol 1020A. Pediatr Infect Dis J. 2015;34(2):162-167. Available at: https://pubmed.ncbi.nlm.nih.gov/25232777.
  10. Ripamonti D, Benatti SV, Di Filippo E, Ravasio V, Rizzi M. Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature. AIDS. 2014;28(7):1077-1079. Available at: https://pubmed.ncbi.nlm.nih.gov/24685746.
  11. Puthanakit T, Bunupuradah T, Kosalaraksa P, et al. Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use. Pediatr Infect Dis J. 2013;32(3):252-253. Available at: https://pubmed.ncbi.nlm.nih.gov/22986704.
  12. Prasertvit P, Chareonyingwattana A, Wattanakrai P. Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity. Contact Dermatitis. 2017;77(6):379-384. Available at: https://pubmed.ncbi.nlm.nih.gov/28782122.
  13. Peter J, Choshi P, Lehloenya RJ. Drug hypersensitivity in HIV infection. Curr Opin Allergy Clin Immunol. 2019;19(4):272-282. Available at: https://pubmed.ncbi.nlm.nih.gov/31145192.
  14. Nishijima T, Gatanaga H, Teruya K, et al. Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting. J Infect Chemother. 2014;20(4):285-287. Available at: https://pubmed.ncbi.nlm.nih.gov/24507978.
  15. Nachman S, Alvero C, Teppler H, et al. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a Phase 1/2 open label, non-randomised, multicentre trial. Lancet HIV. 2018;5(12):e715-e722. Available at: https://pubmed.ncbi.nlm.nih.gov/30527329.
  16. Martin C, Payen MC, De Wit S. Dolutegravir as a trigger for DRESS syndrome? Int J STD AIDS. 2018;29(10):1036-1038. Available at: https://pubmed.ncbi.nlm.nih.gov/29621952.
  17. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579. Available at: https://pubmed.ncbi.nlm.nih.gov/18256392.
  18. Lefebvre M, Walencik A, Allavena C, et al. Rate of DRESS syndrome with raltegravir and role of the HLA-B*53: 01 allele. J Acquir Immune Defic Syndr. 2020;85(4):e77-e80. Available at: https://pubmed.ncbi.nlm.nih.gov/33136758.
  19. Kim GY, Anderson KR, Davis DMR, Hand JL, Tollefson MM. Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: a systematic review of the literature. J Am Acad Dermatol. 2020;83(5):1323-1330. Available at: https://pubmed.ncbi.nlm.nih.gov/32247873.
  20. Hayes E, Derrick C, Smalls D, Smith H, Kremer N, Weissman S. Short-term adverse events with BIC/FTC/TAF: postmarketing study. Open Forum Infect Dis. 2020;7(9):ofaa285. Available at: https://pubmed.ncbi.nlm.nih.gov/32908943.
  21. Hasan M, Yunihastuti E, Abdullah M. Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients. Asian Pac J Allergy Immunol. 2020;12932/AP-080719-0596. Available at: https://pubmed.ncbi.nlm.nih.gov/32061245.
  22. Fillekes Q, Mulenga V, Kabamba D, et al. Is nevirapine dose escalation appropriate in young, African, HIV-infected children? AIDS. 2013;27(13):2111-2115. Available at: https://pubmed.ncbi.nlm.nih.gov/23595153.
  23. Dziuban EJ, Hughey AB, Stewart DA, et al. Stevens-Johnson syndrome and HIV in children in Swaziland. Pediatr Infect Dis J. 2013;32(12):1354-1358. Available at: https://pubmed.ncbi.nlm.nih.gov/23743542.
  24. du Toit JD, Kotze K, van der Westhuizen HM, Gaunt TL. Nevirapine-induced Stevens-Johnson syndrome in children living with HIV in South Africa. South Afr J HIV Med. 2021;22(1):1182. Available at: https://pubmed.ncbi.nlm.nih.gov/33824730.
  25. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008;62(5):879-888. Available at: https://pubmed.ncbi.nlm.nih.gov/18653488.
  26. DiLorenzo MA, Medrano N, Chen JN, et al. Bictegravir-induced drug reaction with eosinophilia and systemic symptoms in a patient with acute human immunodeficiency virus. Open Forum Infect Dis. 2023;10(3):ofad066. Available at: https://pubmed.ncbi.nlm.nih.gov/36879628.
  27. Orkin C, Sadiq ST, Rice L, et al. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects. HIV Med. 2010;11(3):187-192. Available at: https://pubmed.ncbi.nlm.nih.gov/19780860.

Management of Medication Toxicity or Intolerance

Rash and Hypersensitivity Reactions

View full version of Table 17k.
Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions
Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions
  
  
  
  

 

Download Guidelines

Related Content